系统性硬化症相关间质性肺病进展模式与预测因素:EUSTAR队列分析
基于EUSTAR数据库中826例系统性硬化症相关间质性肺病(SSc-ILD)患者,12±3个月内27%出现FVC进展,长期随访中多数为缓慢波动性下降,仅8%持续快速下降;男性、较高mRSS和反流/吞咽困难是5年FVC下降的最强预测因素。
要点
- SSc-ILD病程异质多变,每12个月约23%–27%患者出现FVC进展,但连续进展者少。
- 多数进展者(58%)呈缓慢下降伴稳定/改善期,仅8%快速持续下降,33%无下降发作。
- 男性、较高改良Rodnan皮肤评分和反流/吞咽困难预测5年FVC下降。
核心结论
- SSc-ILD病程异质且多变,应密切监测所有患者,治疗宜在FVC下降前启动以预防进展。
研究设计与样本
- 基于EUSTAR数据库的长期随访研究,纳入基线及12±3个月有FVC测量的SSc-ILD患者826例。
- 对多次FVC测量患者评估长期进展模式,用多变量混合效应模型分析进展预测因素。
主要发现
- 12±3个月内219例(27%)出现进展:FVC下降5%–10%为中度,>10%为显著。
- 535例(65%)有多次FVC测量,平均随访5年,每12个月23%–27%患者进展。
- 58%进展者呈缓慢下降模式,8%快速持续下降,178例(33%)无FVC下降发作。
- 5年FVC下降最强预测因素为男性、较高改良Rodnan皮肤评分和反流/吞咽困难症状。
临床怎么用
- 对所有SSc-ILD患者应密切监测FVC,关注男性、高mRSS及反流/吞咽困难等高危因素。
- 治疗宜在FVC下降前启动,以预防进展和不可逆器官损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD), using data from the European Scleroderma Trials And Research (EUSTAR) database over long-term follow-up. METHODS: Eligible patients with SSc-ILD were registered in the EUSTAR database and had measurements of forced vital capacity (FVC) at baseline and after 12±3 months. Long-term progressive ILD and progression patterns were assessed in patients with multiple FVC measurements. Potential predictors of ILD progression were analysed using multivariable mixed-effect models. RESULTS: 826 patients with SSc-ILD were included. Over 12±3 months, 219 (27%) showed progressive ILD: either moderate (FVC decline 5% to 10%) or significant (FVC decline >10%). A total of 535 (65%) patients had multiple FVC measurements available over mean 5-year follow-up. In each 12-month period, 23% to 27% of SSc-ILD patients showed progressive ILD, but only a minority of patients showed progression in consecutive periods. Most patients with progressive ILD (58%) had a pattern of slow lung function decline, with more periods of stability/improvement than decline, whereas only 8% showed rapid, continuously declining FVC; 178 (33%) experienced no episode of FVC decline. The strongest predictive factors for FVC decline over 5 years were male sex, higher modified Rodnan skin score and reflux/dysphagia symptoms. CONCLUSION: SSc-ILD shows a heterogeneous and variable disease course, and thus monitoring all patients closely is important. Novel treatment concepts, with treatment initiation before FVC decline occurs, should aim for prevention of progression to avoid irreversible organ damage.
引用
- Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2020. PMID: 32988845. doi:10.1136/annrheumdis-2020-217455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。